An artificial capillary culture/transduction technique has readily attainable from 5 × 10 7 CD8-depleted lymphocytes. been developed for application in a phase I gene therapy
Introduction
We have previously shown the efficacy of the anti-HIV hammerhead ribozyme, Rz2, in human T cell lines and primary lymphocytes challenged with HIV.
1,2 Based on these in vitro results, a clinical protocol was developed to evaluate the in vivo safety and potential efficacy of anti-HIV ribozyme gene therapy using HIV discordant siblings. The aims of this phase I trial were to assess the safety of treating HIV-positive individuals with genetically modified T-lymphocytes and the potential efficacy of this therapy. Efficacy will be determined by comparison of the relative in vivo survival of T cells containing the control vector (LNL6) versus T cells containing the anti-HIV ribozyme therapeutic vector (RRz2). CD8-depleted peripheral blood lymphocytes (PBL) obtained from an HIV-negative identical twin donor were independently transduced with LNL6 and RRz2 retroviruses, grown in culture and then infused into the genetically matched HIV-positive recipient.
Since 1990, approximately 180 gene marker and gene therapy clinical protocols for an array of inherited and acquired diseases have been approved in the USA. The majority of these studies used retroviral vectors for gene transfer, with lymphocytes being the target cell for many of these studies. This predominance of lymphocyte gene therapy is due to the involvement of lymphocytes in many inherited and acquired disease states and to the Correspondence: G Symonds Received 18 May 1998; accepted 22 September 1998 relative ease of obtaining and manipulating these cells in culture. Gene therapy studies targeting ADA deficiency: SCID, 3, 4 cancer, 5 and HIV 6, 7 are examples of therapies employing lymphocytes.
All gene therapy protocols have a common challenge: the efficient transfer of the therapeutic gene into the target cell population. For ex vivo techniques, this requires highly efficient gene transfer into a relatively large number of target cells. In recent years, the means of retroviral transduction has been examined and various protocols developed in an attempt to increase transfer efficiency. Numerous experimental techniques have been investigated, including: (1) timing of viral exposure to target cells; (2) mitogenic stimulation of target cells; (3) multiple viral doses; (4) centrifugation; (5) phosphate depletion of the culture medium; (6) concentration/dilution of viral supernatants and/or target cell concentration; (7) use of virus collected from producer cells at lower temperature (32°C versus 36°C): and (8) continuous flow of virus containing medium (VCM). [8] [9] [10] [11] [12] [13] [14] [15] Generally, a combination of techniques has yielded the best results, though the reported improvements in transduction efficiency have been variable. Other techniques investigated, such as coculture of target and viral producer cells 16, 17 appear to be successful, but may not be applicable in a clinical setting.
In addition to the mode of transduction, ex vivo expansion of large numbers of PBL for gene therapy procedures has been restricted by culture conditions. Traditionally, flask suspension culture has been used, 6, 7 but this has practical limitations due to the physical demands (medium and space) of large scale preparations. Alternatively, some protocols have utilised culture bag tech-374 nology for large scale expansion of lymphocytes for clinical use. [18] [19] [20] While this system has benefits over the flask culture system in terms of its larger capacity and manageability, consideration must be given as to how the culture technique will affect the process of retroviral transduction, in addition to cell growth and phenotype of the target cell population.
Here we report the preclinical validation of a culture method using hollow-fibre capillary technology (Cellco Cellmax device) to enable expansion and transduction of large numbers of PBL for clinical use. The modified Cellmax system provides improved conditions for the routine clinical expansion, transduction and harvest of large numbers of Ficoll-purified/CD8 + -depleted PBL. One culture module can readily achieve a 36-fold expansion (from 5 × 10 7 to 1.8 × 10
9
) lymphocytes, with gene transfer efficiencies of 3-30%, within a culture period of 10-14 days. Several factors that may influence the efficiency of transduction within a hollow-fibre culture system are discussed. Additionally, a sensitive, quantitative competitive PCR technique has been developed to assess the level of transduction before infusion of the modified cell populations (LNL6 and RRz2) into the recipient patient and to monitor their relative levels in vivo following infusion.
Results

Preparation of CD4
+ PBL Ficoll/Hypaque purification of whole blood or apheresis product, followed by immuno-adsorption depletion of the CD8 + population (AIS MicroCELLector flasks) yielded an enriched CD4 + PBL population. CD8 + cells were reduced from a median CD4
+
:CD8
+ ratio of approximately 2:1 in the starting PBL preparation to approximately 28:1 after depletion with the anti-CD8 flasks (n = 19). The CD3 + lymphocyte proportion of the mononuclear cell population remained constant during the CD8-depletion process with a median of 72.8% in the predepletion population and 73.2% after-depletion. Levels of pre-or non-lymphocytic mononuclear cells (negative for both CD4 and CD8) remained constant after CD8 depletion at a median 28.2% before depletion and 28.2% after-depletion ( Figure 1a) .
Expansion of CD4
+ PBL The proportion of cells not expressing CD4 and CD8 was assessed in the pre-and post-expansion populations. The post-expansion harvest population showed a marked reduction in the levels of CD4
− cells, with a consequent increase in CD3 + and CD4 + cells, due to an expansion of CD3 +
/CD4
+ cells (Figure 1a ). IL-2 (100 U/ml) was added 40-48 h after OKT3 stimulation. These culture conditions not only suppressed growth of non-lymphocytic cells during the expansion process, but also maintained the levels of CD4 + over CD8 + , yielding a median CD4
+
:CD8
+ ratio of approximately 20:1 following expansion over 10-14 days (Figure 1a) . Comparison of the intensity of post-expansion CD3, CD4 and CD8 surface marker expression with the pre-expansion population (Figure 1b) showed no decrease in the population density of these markers, indicating maintenance of the expression of these three surface markers throughout the culture process. The process of transduction did not appear to have any significant effect on the final harvest yields, viability or FACS profiles (Table 1) .
Based on the results shown in Table 2 , the optimum number of cells for initiation of a CD4
+ PBL culture in a Cellmax PBL capillary module was 5 × 10 7 . With this starting cell number a harvest of 0.5 × 10 9 to 2.9 × 10 9 viable cells within 10-14 days was readily attainable, with a reliable average of 1.7 × 10 9 (viability 83 ± 9%, n = 47). Cell expansion typically followed exponential growth from day 2 of culture and usually plateaued at day 10 of culture, when presumably, expansion became restricted by the cell-surface capacity of the hollow-fibre system. Cartridges inoculated with less than 5 × 10 7 viable cells showed a growth profile characterised by a reduced growth rate and reduced harvest yield but with similar lag times for cell growth (even though the time of culture was extended to 19 days) compared with cells from cartridges inoculated with greater than 5 × 10 7 viable cells (Figure 2) . Decreasing the starting cell number (from 5 × 10 7 to 1 × 10 7 ) also led to a three-fold increase in the expression of CD8 surface marker in the final harvest, apparently due to the extended growth period (Table 2) .
Detection: assessment of transduction efficiency using QC-PCR Accurate quantification of samples using quantitative competitive PCR (QC-PCR) relies on similar amplification efficiency of the added competitor template and the target sequence(s) of interest. A QC-PCR system was developed using a competitor template constructed from RRz2 such that the primer sequences were identical, but the amplicon produced was of a smaller size than either LNL6 (174 bp) or RRz2 (216 bp) ( Figure 3 ). The amplification efficiency of all sequences was determined using DNA isolated from G418-selected CEMT4/LNL6 and CEMT4/RRz2 and the engineered 142bp competitor DNA template. The amplicons produced during 30 to 40 cycles, at two to three cycle increments, were measured and the slope of the curve for the number of PCR cycles versus the amount of amplicon produced was plotted. PCR conditions are detailed in the Materials and methods. The rate of amplification under these conditions was assessed for each amplicon (data not shown). The slope (equivalent to the rate of production) was parallel for all three reactions between 30 to 35 cycles, with amplification plateauing by 40 cycles, consequently 35 PCR cycles were used as standard for all PCRs.
The QC-PCR was further validated to determine the effect of competitor concentration on amplification of DNA containing different concentrations of the target sequences at a 1:1 ratio (LNL6:RRz2). DNA from 10-fold dilutions of CEMT4/LNL6 and CEMT4/RRz2 cells mixed in the ratio of 1:1 were amplified in a PCR with 10-fold increasing competitor concentrations from 10 attomoles/l to 10 attomoles/l. The ratio of the sum of the LNL6 amplicons (A174) and RRz2 amplicons (A216) to the competitor amplicons (A142) plotted against the log of the competitor concentration used is shown in Figure 4 . The results show that at competitor concentrations below 10 −3 attomoles/l there is a consistent linear correlation between competitor and target sequence concentration, where the competitor concentration equals the target concentration when the (A174+A216)/A142 ratio is equal to 1. Therefore, all quantitative determi- nations were performed using competitor concentrations of 10 −3 attomoles/l or less. Under the conditions established, the PCR reaction had a quantitative limit of detection of 0.01%, with 10 −4 attomoles/l competitor. Transduction efficiency of unknown samples was routinely determined using a standard curve containing DNA of known concentration. A two-fold dilution series of standard DNA was prepared by spiking normal CEMT4 cells with decreasing amounts of CEMT4/LNL6 and CEMT4/RRz2 cells at a ratio of 1:1. A specific concentration of competitor was used to spike the DNA for a particular standard curve range. This concentration was predicted to compete with the generation of the diagnostic amplicons sufficiently to be quantitatively detected, but to not out-compete the production of the diagnostic amplicons. For the 0.39% to 6.25% standard curve range, PCR reactions were spiked with 10 −4 attomoles/l competitor, for standard curves Ͼ6.25%, 10 −3 attomoles/l was used. Unknown transduced cell samples were quantified by spiking with the same (10 −4 attomoles/l) concentration of competitor (Figure 5a ) and the ratio of the sum of the intensity of the diagnostic bands to the intensity of the competitor band was read from the standard curve generated by plotting this ratio against percentage of transduced cells (Figure 5b ). In the example PCR shown, linear regression analysis of the data produced a line with the equation y = 0.00763 + 0.27x, where y is the amplification intensity ratio and x equals the percentage of target sequence in the unknown test sample. The test samples comprised DNA isolated from PBL harvested from individual lymphocyte cultures after transduction and expansion in the Cellmax culture system and tested in duplicate. The linear best fit equation had a coefficient of determination (R 2 ) of 0.994 indicating a strong linear relationship between the percentage of cells transduced and the ratio determined for the amplicons. Inter-assay variation was determined by the inclusion of a control DNA sample for each assay. The inter-assay control used for nine separate transduction determination assays had a mean value of 2.86% with a standard deviation of 0.89.
Transduction of PBL in an artificial capillary module
The design of the Cellmax culture system was expected to allow for the concentration and localisation of virus in the ECS (extra capillary space) via ultrafiltration through the culture module capillary pores (30 kDa). To test this premise, 40 ml of PA317/LNL6 VCM was ultrafiltered through the ECS of a precultured Cellmax module (as described in the Materials and methods). The ECS capacity of a module is approximately 12 ml, so a threeto four-fold concentration of VCM was expected. Viral titre was determined (see Materials and methods) in duplicate samples of the original PA317/LNL6 VCM which was injected into the cartridge ECS, the VCM filtrate collected in the reservoir, and the medium drained from the ECS after ultrafiltration. The titres were 1.25 × 10 6 ivp/ml, undetectable (Ͻ1 × 10 4 ivp/ml) and 1.75 × 10 6 ivp/ml respectively (colony assay data not shown). This 1.4-fold increase in viral titre observed in the ECS indicates that concentration was occurring, albeit not to the level anticipated. The reasons for this are possibly due to one or a combination of persistence of viral particles captured in the capillary bed caused by adsorption on to the cellulose acetate capillaries or failure to remove VCM from deep within the capillary bed (less than half the ECS capacity was retrieved after ultrafiltration) and/or possible inactivation of the viral particles by the filtration process. The undetectable titre observed in the filtrate indicates the removal or inactivation of infectious viral particles after passage of VCM through the capillary pores, to a level at least 100-fold lower than was injected into the cartridge ECS.
Several methods which have previously been reported to assist in improving the efficiency of retroviral transduction were examined. Phosphate depletion (PO 4 -free RPMI medium culture before and during transduction), and multiple viral doses (greater than 2 consecutive days) showed no significant improvement in transduction efficiency (data not shown). Experimental analysis regarding the timing of viral exposure to the cell culture indicated that the optimum time to commence transduction was at the onset of IL-2 stimulated growth (Table 3) . This data correlates with the hypothesis that integration of the retroviral provirus requires active cell division. 21 Collection of VCM at 32°C, as opposed to 36°C resulted in a modest improvement in titre (PA317/LNL6 showed an increase from 0.9 × 10 6 ivp/ml to 1.5 × 10 6 ivp/ml and PA317/RRz2 from 0.6 × 10 6 ivp/ml to 0.7 × 10 6 ivp/ml when collected at 32°C as described in Materials and methods). The transduction ability of VCM collected at both temperatures was compared (refer to Materials and methods for transduction conditions). Duplicate 32°C VCM transduced cultures yielded 0.9 × 10 9 viable cells each after 7 days of culture, with 23% and 17% transduction efficiency, as assessed by QC-PCR. The duplicate 36°C had the same cell harvest yield, with a transduction efficiency of 8% each. The untransduced growth control showed no difference in harvest yield, viability or FACS profile. PA317/RRz2, under similar experimental conditions, showed no significant difference with 9% and 8% obtained for 32°C PA317/RRz2 VCM and 11% and 6% for the 36°C VCM transduced cultures.
The results of transduction studies are summarised in Figure 6 . Transduction efficiency, determined by QC-PCR, has been plotted against three variable parameters which may be significant in retroviral gene transfer: (a) the cell number at commencement of transduction; (b) the number of infectious viral particles injected into the 
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All transductions were performed using 36°C collected VCM (either PA317/LNL6 or PA317/RRz2). All cultures had IL-2 added 40-48 h after initiation of the OKT3-stimulated PBL culture and exponential growth typically started 8-24 h later. Transductions were for 2 consecutive days with an average MOI of 2 on each day of transduction.
ECS; and (c) the ratio of viral particles to cell number (multiplicity of infection, MOI). Overall transduction results for VCM collected at 32°C is compared with 36°C collected VCM. The 32°C collected VCM consistently transduced PBL with equivalent or improved efficiency. Figure 6a shows that whilst active cell division is important for stable transduction, the actual number of viable cells in the Cellmax system at the commencement of transduction is not, as four-fold differences in cell estimates at the commencement of transduction showed no apparent influence on the level of transduction. The remaining parameters examined (Figure 6b and c) indicate that for a transduction efficiency greater than 10% there is an optimum range of infectious viral particles (7 × 10 7 to 2 × 10 8 ), which correlates with an apparent MOI optimum of 7 to 20. However, it is apparent that there are additional factors which influence the efficiency of retroviral transduction in a closed system such as the Cellmax.
Discussion
QC-PCR is widely used for quantification of cellular DNA. The QC-PCR technique developed here has been validated for a quantitative range of 50-0.01% with competitor concentrations of 10 −3 to 10 −5 attomoles/l under the conditions detailed in this article. The small variation in the interassay control values (2.86% ± 0.89) indicates the precision and reliability of the assay system. Further analysis of in vivo ratios of the therapeutic to control genes is capable to 0.0001%, with modification to the PCR conditions and cycle times (unpublished observations). Transduction within the Cellmax system yields a minimum transduction efficiency of approximately 3%, with transduction efficiencies of up to 30% possible. The data suggest that there is an equilibrium between infectious viral particles capable of transduction and inhibitory factors, which when displaced, possibly by an increase in noninfectious particles or decreased bio-availability of viable virus, effectively negates the activity of the infectious virus.
Unlike conventional static culture, the closed ECS makes it possible, through ultrafiltration of the VCM, to concentrate and localise virus in close proximity to the proliferating cell population. Retrovirus is unable to escape the ECS as the viral particles are larger than the capillary pore size (30 kDa). Cells present in the ECS are 
᭹, Transduction with VCM collected at 32°C; ̅, transduction with VCM collected at 36°C. All data points are from transductions commenced as soon as exponential growth was detected. Data shown is from the first day of transduction. (a) Transduction efficiency versus cell number at commencement of transduction. All cultures were initiated with approximately 5 × 10 7 viable cells. Transduction commenced as soon as the l-lactate levels indicated cell growth. The viable cell count at this time was estimated by l-lactate production rate for each individual culture. (b) Transduction efficiency versus total number of infectious viral particles injected into the ECS on the first day of transduction. This was calculated according to the titre of the VCM and the volume ultrafiltered through the ECS. (c) Transduction efficiency versus MOI on the first day of transduction. MOI was calculated according to the ratio of infectious viral particles injected to the viable cell number (based on l-lactate production rate).
not washed free of virus between or after transductions, therefore, both viable and non-viable viral particles are concentrated and remain in the cell culture area over the duration of transduction and expansion. This localised concentration effectively increases the MOI, but as the data show, there are other factors involved which influence the degree of retroviral transduction.
We hypothesise that the efficiency of transduction is largely dependent on the 'availability' of infectious viral particles to the target cell population. Availability may be affected in two ways: (1) Adsorption on to the cellulose acetate capillaries or localised concentration of infectious viral particles during the ultrafiltration process. If this area of concentration or adsorption of viral particles is not localised with the target cells, it may effectively reduce cell-virus interaction and subsequent transduction efficiency. (2) It is possible that high numbers of nonviable viral particles in the ECS, which compete with infectious viral particles for available cellular surface receptor binding, inhibit infection of the target population.
Non-viable particles may come from several areas: (1) Viable retrovirus, which has a half-life of 4-8 h at 37°C 21, 22 remains in the ECS, becoming thermally inactivated over time and resulting in an increase of non-viable particles in the culture environment. (2) The action of ultrafiltration through the hollow fibre pores results in shearing of the viral envelope, generating viral particles incapable of infection. Paul and colleagues 21 demonstrated the importance of the pressure used to ultrafiltrate VCM, in the recovery of viable virus following concentration. Pressures of 5 psi with a 50 kDa hollow fibre filter system had a significant detrimental effect on the infectivity of the concentrated virus. Decreasing the input pressure to 2.5 psi greatly reduced the level of viral inactivation through shearing of its envelope proteins. The actual pressure required for ultrafiltration of VCM through the Cellmax capillary pores is unknown, however it is possible that this is a major contributing factor in the success of retroviral transduction. (3) Ultrafiltration of VCM results in co-concentration of inhibitory factors. Forestell and colleagues 13 reported on the presence of inhibitory agents specific to envelope protein in amphotropic virus supernatant preparations, which under conditions of increased MOI, reduced the transduction ability of concentrated viral supernatants. Collection of VCM at 32°C, as opposed to 36°C, reduced this inhibitory effect, presumably due to minimised accumulation of thermally inactivated virus in the VCM preparations. This benefit of 32°C VCM was observed with transductions in the Cellmax system, albeit to varying degrees. The variability of the improvement with 32°C VCM may be attributed to batch to batch variations in VCM production, caused by variations in temperature, culture temperature equilibration time and length of collection period. 22 Other data (not shown) suggest that VCM, when diluted with PA317-conditioned medium resulted in lower transduction efficiencies than the same virus diluted with non-conditioned medium. This correlates with the findings of Forestell and colleagues 13 that the inhibitory factor(s) is specific to amphotropic viral envelope protein. The impact of these above-mentioned points may result in reduced infectivity of freshly added virus in the first and subsequent rounds of transduction.
In summary, capillary culture of cells in a clinical setting has significant advantages over previously used culture techniques. Once established, the culture and transduction of large numbers of lymphocytes is readily achieved within a relatively short culture period of 10-14 days. Additionally, in comparison to conventional culture techniques, the capillary culture/transduction technique allows significant reductions in the amount of space and consumables required for ex vivo culture of PBL for clinical use, and greatly reduces operator handling, thereby minimising operator variations and the risk of contamination during ex vivo manipulations. The current system provides a reliable method for an average 34-fold cell expansion of a small CD4 + -enriched PBL starting population of 5 × 10 7 . These culture/transduction conditions retain the initial phenotype of the CD4 + population with a minimum transduction efficiency of 3-5%, with levels of 30% attainable.
Materials and methods
Production of amphotropic retroviral supernatants
Construction of the PA317-based amphotropic vectors: PA317/LNL6 (vector control) and PA317/RRz2 (ribozyme therapeutic against the translation initiation region of the HIV tat gene) have been previously described. 1 Producer cell lines were expanded in T225 tissue culture flasks (Corning Costar, Brumath, France) at 36°C/5% CO 2 using Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) 10% foetal bovine serum (FBS; Trace Biosciences, Sydney, Australia). Collection of 32°C virus containing medium (VCM) commenced when the cells were at a density of approximately 1.5 × 10 5 cells/cm 2 (t 0 ). At t 0 , the medium was replenished with 30 ml DMEM or Iscove's modified Dulbecco's medium (IMDM, Gibco BRL) + 10% FBS and the temperature reduced to 32°C. Twenty-four hours later (t 24 ) the medium was collected, 0.45 m filtered and frozen at −80°C. At the time of VCM collection, the medium was replenished with a further 30 ml of fresh culture medium, and the above VCM collection process was repeated at 48 h (t 48 ), with the final VCM collection at 72 h (t 72 ). The three collections were thawed, combined, 0.2 m filtered and stored at −80°C. 1-ml samples from each collection point and the pooled VCM were also aliquoted for titering. For 36°C VCM, the temperature was maintained at 36°C.
Titering of amphotropic retroviral supernatants VCM was titrated using serial 10-fold dilutions with 8 g/ml polybrene medium and exposure to NIH 3T3 TK − cells at a density of 70-80% confluence for 24 h as previously described. 23 After infection, cells were selected for G418 (neomycin) resistance using 600-800 g/ml Geneticin (Gibco BRL) in DMEM + 10% FBS.
Source of primary peripheral blood lymphocytes (PBL) PBL were obtained from buffy coats (Red Cross Blood Bank, Sydney, Australia) or leukapheresis samples obtained from healthy donors. Leukapheresis was performed by the Cell Separation Unit, St Vincent's Hospital, Sydney and 40-70 ml of peripheral blood lymphocytes collected. All blood products tested negative for standard blood screening tests.
Preparation of CD8
+ depleted PBL Purified peripheral blood mononuclear cells (PBMC) were obtained by Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation of heparin (David Bull Laboratories, Sydney, Australia) treated (25 U/ml) buffy coat or leukapheresis samples. The PBMC layer was washed and depleted of CD8 + cells by adhesion to anti-CD8 coated flask (MicroCELLector; Applied Immune Sciences, Santa Clara, CA, USA). Approximately 1.2 × 10 8 cells were added to a T150 flask according to the manufacturer's recommendations.
Immunofluorescent staining and FACS analysis
Flow cytometric analysis was performed on both preand post-expansion PBL samples. Using 1 × 10 6 cells per reaction, cells were stained with: 5 l CD3-PerCP + 5 l CD4/8-FITC/PE for three-colour antibody staining, 5 l IgG-PerCP + 5 l IgG-FITC/PE for the isotype control and 10 l PBS for the negative control. All antibodies were obtained from Becton Dickinson (San Jose, CA, USA). After antibody incubation at 4°C for 15 min, cells were washed with 5 ml of cold PBS + 5% FBS. For immediate analysis, washed cells were resuspended in 1 ml PBS, otherwise cells were preserved in 1 ml 0.5% paraformaldehyde in PBS and stored at 4°C in a light protected environment until time of analysis (not longer than 5 days). Analysis of CD3
+ T cell subsets was performed using a FACSort (Becton Dickinson) with CellQuest software.
Preculture of the Cellmax capillary module Spectrum (Laguna Hills, USA) Cellmax cartridges MPS450-011 were used for all experiments. The cartridges have an ECS of 11-12 ml and modified cellulose capillaries with a nominal molecular weight cut off of 30 kDa.
Culture modules were set up according to the manufacturer's instructions, with the following modifications: (1) insertion of a three-way stop cock in the flow path tubing/cartridge inlet junction, which made for easier priming of the system at time of set-up and throughout the pre-culture period; (2) ECS fluid was not drained at time of pre-culture set-up or inoculation; rather both preculture media and inoculum were directly injected into the ECS and the existing contents displaced by ultrafiltration through the capillary pores. Excess volume ultrafiltered through the capillary pores was collected in the reservoir. This method reliably allowed us to obtain and maintain bubble-free conditions in the module. Modules were pre-cultured with 4 × 100 ml culture medium (AIM-V (Gibco BRL) + 5% FBS) over a 2-4-day period before inoculation (with a flow rate of 25 ml/min).
Culture of CD8
+ depleted PBL Approximately 5 × 10 7 CD8 + depleted PBL were resuspended in a total volume of 15 ml AIM-V medium or VCM with 50 ng/10 7 cells of OKT3 (Orthoclone; JanssenCilag, Sydney, Australia) and incubated 15-30 min at 37°C/5% CO 2 . After incubation, the 15-ml cell suspension was inoculated into the ECS of a pre-cultured Cellmax cartridge by syringing the 15 ml cell suspension directly into a cartridge side port and gently oscillating between a second syringe connected to the other cartridge side port. Volume in excess of the ECS capacity was then ultrafiltered through the capillary pores and into the module reservoir, leaving the cells in the ECS amongst the capillary bed. Modules were connected to the pump station and the flow rate set to approximately 25 ml/min.
Cell metabolism was monitored daily by quantifying levels of l-lactate in the module reservoir using Sigma (St Louis, MO, USA) l-lactate reagent and standards (1.2, 0.8, 0.4 and 0.2 mg/ml). The daily lactate production rate was calculated and used to estimate the viable cell number, based on the approximation that 4 × 10 6 PBL will produce 1 mg/day lactate. When lactate levels exceeded 0.6 mg/ml, the cultures were fed by either addition or complete change of fresh culture medium, depending on the current reservoir volume and l-lactate production rate. During the first 5-6 days of culture, cultures were always fed by addition of fresh medium to the conditioned medium reservoir. When the lactate production rate reached у100 mg/day, the pump speed was increased to 50-55 ml/minute to provide adequate medium exchange for the expanding cell population.
To encourage preferential expansion of the CD4 + population, 100 U/ml IL-2 (rIL-2; Chiron, Emeryville, CA, USA) was added 40 h after stimulation with OKT3. This concentration of IL-2 was maintained throughout the culture period, while the level of FBS was gradually reduced so the cells were growing in virtually serum-free conditions by day 10 of culture (less than 0.1% remaining).
Transduction of PBL within the Cellmax system Retroviral transduction was performed by direct injection of VCM through the cartridge side ports into the ECS. Viral particles were retained and concentrated within the ECS by ultrafiltration through the capillary pores. If the injected VCM volume was greater than the ECS capacity (approximately 12 ml), the VCM filtrate was collected into a waste reservoir and then discarded, otherwise the VCM filtrate was retained in the medium reservoir.
Before commencement of transduction, IL-2 (100 U/ml) and protamine sulphate (Fisons, Sydney, Australia) (5 g/ml) were added to the VCM, and protamine sulphate added to the culture reservoir for a final concentration of 5 g/ml. Throughout the transduction procedure, IL-2 and protamine sulphate were maintained at these levels. Protamine sulphate (MW 5 kDa) is able to pass through the 30 kDa capillary pores during the transduction process and equilibrate between the ECS and the reservoir environments. Many various transduction procedures were investigated: (1) The effect of timing of the commencement of transduction was assessed by comparing the effect of transduction immediately following OKT3 stimulation, at the time of IL-2 addition, as soon as IL-2-stimulated growth was detected in the cultures (typically 6-24 h after IL-2-addition), or until an exponential growth pattern was established (up to day 4 of culture); (2) The duration of transduction (number of consecutive days); (3) The frequency of transduction, ie once or up to three times in a 24-h period; (4) Phosphatefree culture conditions were evaluated by initiating and maintaining cultures in NaPO 4 free RPMI 1640 medium (Gibco BRL) + 5% FBS. The culture reservoir was replaced with AIM-V + 5% FBS, 24 h after the final transduction procedure; (5) MOI was varied by increasing or decreasing the volume of VCM ultrafiltered through the ECS; (6) Viral titre was varied by pre-dilution of VCM with either PA317-conditioned medium or with DMEM + 10% FBS; (7) Efficacy of 32°C versus 36°C collected VCM was assessed by establishing five cultures from a single CD8 + -depleted PBL preparation (including one culture for an untransduced growth control). Transduction was performed in duplicate for both 32°C-collected PA317/LNL6 VCM and 36°C-collected PA317/LNL6 VCM, under identical conditions: 2 consecutive days of transduction, starting on day 2 of culture, approximately 8 h after addition of 100 U/ml IL-2 to the culture reservoir. Protamine sulphate (5 g/ml) was added to the culture reservoir at the initiation of transduction and also to the VCM preparation. The daily injected VCM volume yielded a MOI equivalent to 2 on each day of transduction (based on l-lactate production rate and predetermined viral titre) and the total number of infectious viral particles injected was between 0.4-2 × 10 8 on the first day of transduction, and doubled on the second day, to normalise for the increase in cell number.
Harvest of cells from the capillary module
Harvest was performed once cultures had reached the plateau growth phase (as determined by no further increase in l-lactate production rate (mg/day) for 2 or more consecutive days). Cells were harvested according to the manufacturer's instructions, however reservoir medium was injected into the ECS through the capillary pores using a 50 ml syringe attached to the stop-cock (inserted at the time of preculture set-up). A total volume of 200-225 ml was collected in this manner. Once harvested, the cells were washed three times with a solution of 0.18% NaCl + 4% glucose (Baxter Healthcare, Sydney, Australia) with 5% Albumex20 (a 20% solution of human serum albumin from Commonwealth Serum Laboratories, Melbourne, Australia).
Pre-harvest sampling was performed 2 days before the anticipated day of harvest. This involved harvesting a small (5-6 ml) cell sample from the ECS and removal of 18-20 ml from the culture reservoir. These samples were used to perform sterility testing (aerobic and anaerobic bacteria and fungi, and mycoplasma) and for assessment of transduction efficiency before harvest and preparation of the recipient for infusion. All sterility testing services were performed by the St Vincent's Hospital Microbiology Department.
Quantitative competitive PCR Transduction efficiency was assessed using quantitative competitive PCR (QC-PCR). 24 Primers 5L1A (5′-GAG TTC TAC CGG CAG TGC AAA-3′) and 3L2A (5′-CAC TCA TGA GAT GCC TGC AAG-3′) were designed to amplify a region of the neo gene in which the therapeutic gene, Rz2, was cloned. 25 Amplification of the control vector (LNL6) produces a 174 bp amplicon while amplification of the vector containing the therapeutic (RRz2) produces a 216 bp amplicon (Figure 3a) . Details of competitor construction are as shown in Figure 3b .
Standards (controls with known percentages of LNL6-and RRz2-containing cells) were produced by spiking non-transduced CEMT4 cells (human T-lymphoblastoid cell line from NIH AIDS Research and Reference Reagent Program) with CEMT4 cells transduced with PA317/LNL6 and PA317/RRz2. The CEMT4/LNL6 and CEMT4/RRz2 were selected with G418 (600 g/ml) to ensure 100% of the cultures expressed the constructs. DNA was isolated from 5 × 10 6 cells using the Gnome DNA Isolation Kit (Bio 101, Vista, CA, USA) according to the manufacturer's instructions. DNA (150 ng) was amplified with a known competitor concentration under the following conditions: 2 mm MgCl 2 , 0.2 mm each dNTP (Pharmacia Biotech), 0.4 mm each primer, 10 mm Tris-HCl (pH 8.3), 50 mm KCl and 0.25 units AmpliTaq DNA polymerase (Perkin Elmer, Foster City, CA, USA). Reactions took place in a total volume of 50 l and included wax beads (Ampliwax PCR Gem 100; Perkin Elmer) to ensure a 'hot start'. The samples were amplified for one round at 94°C for 3 min followed by 35 cycles of annealing at 68°C for 30 s and denaturation at 94°C for 30 s in a PE2400 thermocycler (Perkin Elmer). A range of standards was included in each PCR run to allow direct comparison of unknown samples with the standard curve. PCR mix (10 l) was added to 5 l of RNA loading dye, denatured (5 min, 95-100°C), and separated on a 5% denaturing polyacrylamide gel. The gel was fixed, dried and exposed on a phosphorimaging screen (Molecular Dynamics, Sunnyvale, CA, USA). The diagnostic amplicons were then analysed by ImageQuant software (Molecular Dynamics). Following subtraction of background intensity, the diagnostic/competitor ratio for the standard curve was calculated by dividing the sum of the diagnostic bands by the competitor band, and this ratio plotted against the known percentages of the standards. The transduction efficiency of unknown samples was calculated by linear regression using Cricket Graph software. In addition, the ratio of LNL6-versus RRz2-containing cells was determined by dividing the intensity of the LNL6 amplicon by the intensity of the RRz2 amplicon (after subtraction of background intensity for each band).
Primer labelling QC-PCR used a radioactively labelled 5′ primer. 26 picomole 5L1A end-labeled with 100 picomole ␥ 32 P-dATP using the RTS T4 kinase labelling system (Gibco BRL) in a total volume of 20 l at 37°C for 30 min. The reaction was inactivated by incubating at 55°C for 5 min.
Marker labelling pUC19/Hpa II markers 26-501 bp (Bresatec, Adelaide, Australia) were labeled by incubation at 37°C for 30 min with 2 U Klenow (Boehringer Mannheim, Germany), 2 l ␣ 32 P-dCTP, 1 l dCTP labelling mix (Pharmacia Biotech), 2 l 10 × Buffer L (Boehringer Mannheim) in a total reaction volume of 20 l. The labeled marker was then purified with a Biospin 30 column (BioRad, Hercules, CA, USA).
